This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine

Acute myeloid leukemia is a heterogenous group of distinct malignancies that accounts for 80% of acute leukemias in adults. Recent advancements in diagnostic tests, such as next-generation sequencing, have led to the identification of unique biomarkers associated with acute myeloid leukemia. These advancements, along with new targeted therapies, offer hope for a greater impact of survival for patients with this disease.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.